By Bhanvi Satija and Christy Santhosh (Reuters) -Talks with the Trump administration about lowering U.S. drug prices have so ...

Compounded GLP-1s are still accessible on telehealth sites, despite an agreement with Eli Lilly to cease copycat sales.

Eli Lilly (NYSE:LLY ... The latest executive order on drug prices by President Donald Trump has only added to its woes, or has it? The order signed on May 12 aims to align U.S. drug prices ...

While pharmaceutical executives raise valid concerns about the lack of detailed implementation plans for the “Most Favored ...

Pharmaceutical stocks, including Merck (MRK), Pfizer (PFE), and Eli Lilly (LLY ... a new executive order that will push drugmakers to sell prescription drugs at a lower price and directly to ...

If Eli Lilly presents strong data, the stock could be set to rally and potentially be on a path to reaching new highs. Should ...

These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing ...

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will ...

(Reuters) -Indian contract drug manufacturer OneSource Specialty Pharma expects strong growth in its order book over the next three years, driven by the global boom in weight-loss drugs, its top ...

Eli Lilly, the drugmaker behind the blockbuster weight loss drug Zepbound, is suing four telehealth companies for allegedly selling illegal copies of the drug made by compounding pharmacies.